Novo Nordisk faces intensifying GLP-1 competition, notably from Eli Lilly, prompting price cuts for Wegovy to expand market access and defend share. NVO's long-term upside relies on broadening ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback